Q4 2025 FINANCIAL RESULTS PAT MILES, CHAIRMAN & CEO | TODD KNING, EVP & CFO | FEBRUARY 24, 2026 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking stateme ...

Core Insights - Alphatec Holdings, Inc. (ATEC) has secured exclusive U.S. rights to market and distribute Theradaptive's OsteoAdapt® platform, marking a significant partnership in the spine industry aimed at enhancing spinal fusion outcomes [2][4] - Theradaptive has initiated a Series B investment round to support the expansion of its protein-engineering technology and the advancement of clinical studies related to OsteoAdapt [5][6] Company Overview - ATEC is focused on revolutionizing spine surgery through innovative solutions and has developed a procedural ecosystem that integrates informatics, imaging, navigation, and instrumentation [4][7] - Theradaptive is a clinical-stage regenerative medicine company that specializes in engineered protein therapeutics for various medical applications, including spine and orthopedic treatments [8] Technology and Market Potential - OsteoAdapt utilizes proprietary AMP2™ protein technology and is currently undergoing clinical trials, having received three FDA Breakthrough Device Designations, indicating its potential to meet significant medical needs in bone regeneration [3][6] - The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, positioning OsteoAdapt as a transformative solution in the market [6]